222 related articles for article (PubMed ID: 33636166)
1. Suppression of α-synuclein propagation after intrastriatal injection in FABP3 null mice.
Matsuo K; Kawahata I; Melki R; Bousset L; Owada Y; Fukunaga K
Brain Res; 2021 Jun; 1760():147383. PubMed ID: 33636166
[TBL] [Abstract][Full Text] [Related]
2. Fatty Acid Binding Protein 3 Enhances the Spreading and Toxicity of α-Synuclein in Mouse Brain.
Yabuki Y; Matsuo K; Kawahata I; Fukui N; Mizobata T; Kawata Y; Owada Y; Shioda N; Fukunaga K
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32210174
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MPTP-induced α-synuclein oligomerization by fatty acid-binding protein 3 ligand in MPTP-treated mice.
Matsuo K; Cheng A; Yabuki Y; Takahata I; Miyachi H; Fukunaga K
Neuropharmacology; 2019 May; 150():164-174. PubMed ID: 30930168
[TBL] [Abstract][Full Text] [Related]
4. Crucial Role of FABP3 in αSyn-Induced Reduction of Septal GABAergic Neurons and Cognitive Decline in Mice.
Matsuo K; Yabuki Y; Melki R; Bousset L; Owada Y; Fukunaga K
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401521
[TBL] [Abstract][Full Text] [Related]
5. An α-synuclein decoy peptide prevents cytotoxic α-synuclein aggregation caused by fatty acid binding protein 3.
Fukui N; Yamamoto H; Miyabe M; Aoyama Y; Hongo K; Mizobata T; Kawahata I; Yabuki Y; Shinoda Y; Fukunaga K; Kawata Y
J Biol Chem; 2021; 296():100663. PubMed ID: 33862084
[TBL] [Abstract][Full Text] [Related]
6. Development of FABP3 ligands that inhibit arachidonic acid-induced α-synuclein oligomerization.
Cheng A; Shinoda Y; Yamamoto T; Miyachi H; Fukunaga K
Brain Res; 2019 Mar; 1707():190-197. PubMed ID: 30496735
[TBL] [Abstract][Full Text] [Related]
7. Novel FABP3 ligand, HY-11-9, ameliorates neuropathological deficits in MPTP-induced Parkinsonism in mice.
Wang H; Fukunaga K; Cheng A; Wang Y; Arimura N; Yoshino H; Sasaki T; Kawahata I
J Pharmacol Sci; 2023 May; 152(1):30-38. PubMed ID: 37059489
[TBL] [Abstract][Full Text] [Related]
8. FABP3 protein promotes α-synuclein oligomerization associated with 1-methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity.
Shioda N; Yabuki Y; Kobayashi Y; Onozato M; Owada Y; Fukunaga K
J Biol Chem; 2014 Jul; 289(27):18957-65. PubMed ID: 24855640
[TBL] [Abstract][Full Text] [Related]
9. Fatty Acid-Binding Protein 3 is Critical for α-Synuclein Uptake and MPP
Kawahata I; Bousset L; Melki R; Fukunaga K
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661838
[TBL] [Abstract][Full Text] [Related]
10. α-Synuclein decoy peptide protects mice against α-synuclein-induced memory loss.
Guo Q; Kawahata I; Jia W; Wang H; Cheng A; Yabuki Y; Shioda N; Fukunaga K
CNS Neurosci Ther; 2023 Jun; 29(6):1547-1560. PubMed ID: 36786129
[TBL] [Abstract][Full Text] [Related]
11. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
12. Impact of fatty acid-binding proteins and dopamine receptors on α-synucleinopathy.
Kawahata I; Fukunaga K
J Pharmacol Sci; 2022 Feb; 148(2):248-254. PubMed ID: 35063140
[TBL] [Abstract][Full Text] [Related]
13. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
[TBL] [Abstract][Full Text] [Related]
14. Dose-related biphasic effect of the Parkinson's disease neurotoxin MPTP, on the spread, accumulation, and toxicity of α-synuclein.
Merghani MM; Ardah MT; Al Shamsi M; Kitada T; Haque ME
Neurotoxicology; 2021 May; 84():41-52. PubMed ID: 33549656
[TBL] [Abstract][Full Text] [Related]
15. Fatty Acid-Binding Protein 3 Expression in the Brain and Skin in Human Synucleinopathies.
Oizumi H; Yamasaki K; Suzuki H; Hasegawa T; Sugimura Y; Baba T; Fukunaga K; Takeda A
Front Aging Neurosci; 2021; 13():648982. PubMed ID: 33841128
[TBL] [Abstract][Full Text] [Related]
16. Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers.
Boi L; Pisanu A; Palmas MF; Fusco G; Carboni E; Casu MA; Satta V; Scherma M; Janda E; Mocci I; Mulas G; Ena A; Spiga S; Fadda P; De Simone A; Carta AR
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198335
[TBL] [Abstract][Full Text] [Related]
17. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
[TBL] [Abstract][Full Text] [Related]
18. Neuropathology of α-synuclein in Parkinson's disease.
Choong CJ; Mochizuki H
Neuropathology; 2022 Apr; 42(2):93-103. PubMed ID: 35362115
[TBL] [Abstract][Full Text] [Related]
19. Rab7 reduces α-synuclein toxicity in rats and primary neurons.
Szegö EM; Van den Haute C; Höfs L; Baekelandt V; Van der Perren A; Falkenburger BH
Exp Neurol; 2022 Jan; 347():113900. PubMed ID: 34695425
[TBL] [Abstract][Full Text] [Related]
20. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
